4 Endocrinology Headlines You Missed in August 2026

August brought a wave of movement across diabetes care, from a new cardiovascular indication for one of the field’s top-selling therapies, tirzepatide, to the first device capable of tracking ketones and glucose together. On the trial-data side, avexitide displayed strong phase 3 results in a condition with no approved therapies (post-bariatric hypoglycemia), and this month’s Diabetes Dialogue podcast explored topline retatrutide data alongside a sobering look at online GLP-1 prescribing practices.